Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Number of holders
-
166
-
Total 13F shares, excl. options
-
28,447,747
-
Shares change
-
+4,511,028
-
Total reported value, excl. options
-
$1,323,221,426
-
Value change
-
+$216,701,139
-
Put/Call ratio
-
91.83%
-
Number of buys
-
94
-
Number of sells
-
-60
-
Price
-
$46.52
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2019
212 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2019.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 166 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28,447,747 shares
of 207,440,936 outstanding shares and own 13.71% of the company stock.
Largest 10 shareholders include Bellevue Group AG (4,057,411 shares), Meditor Group Ltd (2,679,835 shares), Pentwater Capital Management LP (2,435,500 shares), VANGUARD GROUP INC (2,247,286 shares), BlackRock Inc. (1,983,420 shares), STATE STREET CORP (1,592,981 shares), Partner Fund Management, L.P. (1,555,112 shares), CREDIT SUISSE AG/ (1,061,324 shares), BOXER CAPITAL, LLC (975,000 shares), and WASATCH ADVISORS INC (638,375 shares).
This table shows the top 166 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.